Rybrevant Faspro Wins FDA Nod in Advanced Head and Neck Cancer
FDA grants accelerated approval to subcutaneous amivantamab for recurrent or metastatic HNSCC after a 42% response rate in OrigAMI-4. Eligibility, data, safety and next steps.
Rybrevant Faspro Wins FDA Nod in Advanced Head and Neck Cancer
FDA grants accelerated approval to subcutaneous amivantamab for recurrent or metastatic HNSCC after a 42% response rate in OrigAMI-4. Eligibility, data, safety and next steps.
FDA Approves Bayer’s Sunharbo (Asundexian), the First Factor XIa Inhibitor to Prevent Repeat Stroke
Bayer’s Sunharbo (asundexian) is the first factor XIa inhibitor approved by the FDA. It cut ischemic stroke risk by 26% in 12,327 patients after a recent stroke or high-risk TIA.
India Healthcare and Life-Sciences Startups Raised a Reported $173 Million Across 19 Rounds in October 2026
How to read healthcare startup investment India data for October 2026: a reported $173 million, concentration in one deal and why trackers disagree.
French Blood Banks Hit by Reported Cyberattack on Cold-Storage Equipment, Authorities Investigate
What the reported French blood bank incident means for healthcare cybersecurity: contained impact, open questions and the business case for resilience.
Smith+Nephew Says Talks With J&J Have Ended and Cuts 2026 Outlook as US Hip and Knee Sales Weaken
What the end of Smith+Nephew’s J&J talks means for MedTech mergers and acquisitions: a second guidance cut, an Orthopaedics review and many open questions.
HRV Pharma Signs Deal to Acquire Germany’s Phatebo GmbH, Its First Finished Formulations Business
Why this Indian pharma acquisition matters: HRV Pharma’s purchase of Germany’s Phatebo diversifies an API business, but price and closing are undisclosed.
Lupin Q2 FY27 Results: Sales Rise 14% but Net Profit Falls 22% as Costs Climb
Why the Lupin profit decline of 22.2% happened despite 14% sales growth: employee, manufacturing and depreciation costs, and what management has not said.
Emcure Pharma Q2 FY27 Results: Revenue Up 24.3% as International Business Surges and Guidance Rises
Why the Emcure FY27 guidance matters: revenue growth above 20%, margin expansion and a net cash target, with the debt and execution risks behind it.
Cerus RedeS Phase 3 Trial Meets Primary Endpoint for INTERCEPT Red Blood Cells
What the Cerus RedeS result means for blood safety technology: a Phase 3 win on haemoglobin, an investigational US status and open commercial questions.
